The new multiplex cytokine and cytotoxicity assays as a part of the Opto Cell Therapy Development 1.0 workflow will help users of the Berkeley Lights' platform develop cancer immunotherapies faster Today, Berkeley Lights, Inc., a leader in Digital Cell Biology, launched new capabilities to empower the Opto Cell Therapy Development 1.0 workflow. The workflow consists of a collection of software capabilities, reagents, and protocols to be run on the Beacon(R) and LightningTM systems. With the new